Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873338 · ClinicalTrials.gov registry record · Phase 2
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT02873338 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 75 participants.
The verdict
NCT02873338, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This was an exploratory Phase 2, open label, randomized, multicenter, parallel group study to determine whether there was evidence that the addition of dociparstat (CX-01) at 2 different does levels to standard induction therapy (cytarabine+idarubicin, "7+3") and consolidation therapy had an additive therapeutic effect for subjects newly diagnosed with acute myeloid leukemia (AML) when compared with subjects receiving standard induction chemotherapy alone.
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Dociparstat sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2016-08 |
| Est. Completion | 2019-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873338
The ClinicalTrials.gov registry entry for NCT02873338 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT02873338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02873338 about?
NCT02873338 is a clinical study titled "Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia". This was an exploratory Phase 2, open label, randomized, multicenter, parallel group study to determine whether there was evidence that the addition of dociparstat (CX-01) at 2 different does levels to standard induction therapy (cytarabine+idarubicin, "7+3") and consolidation therapy had an additiv...
What is the current status of trial NCT02873338?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2016-08. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02873338?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), Dociparstat sodium (DRUG).
Who is sponsoring clinical trial NCT02873338?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.